substances to make reference standards for distribution to their customers.

Dated: May 28, 2014.

Joseph T. Rannazzisi,Deputy Assistant Administrator.

[FR Doc. 2014–12972 Filed 6–3–14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: AUSTIN PHARMA, LLC

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before August 4, 2014.

ADDRESSES: Written comments should be to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, and dispensers of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control

("Deputy Assistant Administrator") pursuant to sec. 7(g) of 28 CFR part 0, subpart R, App.

In accordance with 21 CFR 1301.33(a), this is notice that on March 27, 2014, Austin Pharma, LLC., 811 Paloma Drive, Suite C, Round Rock, Texas 78665–2402, applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Schedule
Marihuana (7360)	
Tetrahydrocannabinols (7370)	

The company plans to manufacture bulk synthetic active pharmaceutical ingredients (APIs) for distribution and new product development to its customers. The company plans to bulk manufacture a synthetic tetrahydrocannabinol.

In reference to drug code 7360, the company plans to manufacture a synthetic cannabinol in bulk for sale to its customers. The controlled substance will be further synthesized to bulk manufacture a synthetic tetrahydrocannabinol (7370). No other activity for this drug code is authorized for this registration.

Dated: May 28, 2014.

Joseph T. Rannazzisi,

Deputy Assistant Administrator. [FR Doc. 2014–12944 Filed 6–3–14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. DEA-392]

Manufacturer of Controlled Substances Registration: Cayman Chemical Company

ACTION: Notice of registration.

SUMMARY: Cayman Chemical Company applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances. The DEA grants Cayman Chemical Company registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated December 31, 2013, and published in the **Federal Register** on January 10, 2014, 79 FR 1889, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108, applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cayman Chemical Company to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verified the company's compliance with state and local laws, and reviewed the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of narcotic or non-narcotic controlled substances listed:

Controlled substance	Schedule
Cathinone (1235)	ı
Cathinone (1235) Methcathinone (1237) 4-Methyl-N-methylcathinone (1248)	1
4-Methyl-N-methylcathinone (1248)	1
N-Ethylamphetamine (1475)	1
N,N-Dimethylamphetamine (1480)	1
Aminorex (1585)	1
N-Ethylamphetamine (1475) N,N-Dimethylamphetamine (1480) Aminorex (1585)	1
Gamma Hydroxybutyric Acid (2010)	1
JWH-250 (6250)	1
XLR11 (7011)	1
IWH-019 (7019)	1
AKB48 (7048)	1
JWH-081 (7081)	1
SR-19 also known as RCS-4 (7104)	1
I-Pentyl-3-(1-naphthoyl)indole (7118)	1
JWH-122 (7122)	1

Controlled substance	Schedule
UR-144 (7144)	I
1-Butyl-3-(1-naphthoyl)indole (7173)	
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl) indole (7200)	1
JWH-203 (7203)	i
Alpha-ethyltryptamine (7249)	1
5-(1,1-Dimethylheptyl)-2-[(1R,3S)	
3-hydroxycyclohexyl]-phenol (7297)	1
Lysergic acid diethylamide (7315)	i
2,5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)	1
Marihuana (7360)	Į.
Tetrahydrocannabinols (7370)	1
2C-T-2 (7385)	i
3,4,5-Trimethoxyamphetamine (7390)	1
4-Bromo-2,5-dimethoxyamphetamine (7391)	!
4-Bromo-2,5-dimethoxyphenethylamine (7392)	1
2,5-Dimethoxyamphetamine (7396)	i
JWH-398 (7398)	1
2,5-Dimethoxy-4-ethylamphetamine (7399)	!
3,4-Methylenedioxyamphetamine (7400)	1
N-Hydroxy-3,4-methylenedioxyamphetamine (7402)	i
3,4-Methylenedioxy-N-ethylamphetamine (7404)	1
3,4-Methylenedioxymethamphetamine (7405)	!
4-Methoxyamphetamine (7411)	l I
Alpha-methyltryptamine (7432)	i
Bufotenine (7433)	İ
Diethyltryptamine (7434)	!
Dimethyltryptamine (7435)	1
Psilocybin (7437)	i I
5-Methoxy-N,N-diisopropyltryptamine (7439)	İ
N-Ethyl-1-phenylcyclohexylamine (7455)	1
N-Benzylpiperazine (7493)	1
2C-E (7509)	i
2C-H (7517)	İ
2C-I (7518)	!
2C-C (7519)	1
2C-P (7524)	i
2C-T-4 (7532)	1
MDPV (7535)	Į.
Methylone (7540)	1
Desmorphine (9055)	i
Dihydromorphine (9145)	1
Heroin (9200)	1
Morphine-N-oxide (9307)	1
Tilidine (9750)	i
Amphetamine (1100)	İl
Methamphetamine (1105)	II
Lisdexamfetamine (1205)	II II
Phencyclidine (7471)	II
Phenylacetone (8501)	ii
Codeine (9050)	II.
Dihydrocodeine (9120)	II II
Oxycodone (9143)	II
Hydrocodone (9193)	ii
Lévomethorphan (9210)	II
Meperidine (9230)	II II
Meperidine intermediate-B (9233)	II II
Dextropropoxyphene, bulk (non-dosage forms) (9273)	II
Morphine (9300)	ii
Thebaine (9333)	II.
Oxymorphone (9652)	II

Controlled substance	Schedule
Sufentanil (9740)	II II

The company plans to manufacture reference standards for distribution to their research and forensics customers.

In reference to drug code 7360 (Marihuana), the company plans to bulk manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk manufacture a synthetic tetrahydrocannabinol (7370). No other activity for this drug code is authorized

No comments or objections have been received.

Dated: May 28, 2014.

Joseph T. Rannazzisi,

for this registration.

Deputy Assistant Administrator.

[FR Doc. 2014–12952 Filed 6–3–14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Manufacturer of Controlled Substances Registration: Noramco, Inc.

ACTION: Notice of registration.

SUMMARY: Noramco, Inc. applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances. The DEA grants Noramco, Inc. registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated December 23, 2013, and published in the **Federal Register** on January 8, 2014, 79 FR 1390, Noramco, Inc. (GA), 1440 Olympic Drive, Athens, Georgia 30601, applied to be registered as a manufacturer of certain basic classes of narcotic or non-narcotic controlled substances.

The Drug Enforcement Administration (DEA) has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security

systems, verified the company's compliance with state and local laws, and reviewed the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the basic classes of narcotic or non-narcotic controlled substances listed:

Controlled substance	Schedule
Gamma Hydroxybutyric Acid (2010).	I
Dihydromorphine (9145)	1
Morphine-N-oxide (9307)	1
Codeine-N-oxide (9053)	1
Amphetamine (1100)	II
Methylphenidate (1724)	II
Codeine (9050)	II
Dihydrocodeine (9120)	II
Oxycodone (9143)	H
Hydromorphone (9150)	H
Hydrocodone (9193)	H
Morphine (9300)	H
Oripavine (9330)	II
Thebaine (9333)	П
Opium tincture (9630)	П
Oxymorphone (9652)	П
Noroxymorphone (9668)	П
Alfentanil (9737)	П
Remifentanil (9739)	П
Sufentanil (9740)	II
Carfentanil (9743)	II
Tapentadol (9780)	II
Fentanyl (9801)	II

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

No comments or objections have been received.

Dated: May 28, 2014.

Joseph T. Rannazzisi,

Deputy Assistant Administrator. [FR Doc. 2014–12954 Filed 6–3–14; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Office of Justice Programs [OJP (OJP) Docket No. 1654]

Request for Nominations to the Office of Justice Programs' Science Advisory Board

AGENCY: Office of Justice Programs (OJP), DOJ.

ACTION: Notice of Request for Nominations.

SUMMARY: This notice announces that OJP is seeking nominations of individuals to serve on the OIP Science Advisory Board ("Board"). The Board was established by the Attorney General in 2010. It is chartered to provide OJP, a component of the Department of Justice, with valuable advice in the areas of science and statistics for the purpose of enhancing the overall impact and performance of its programs and activities in criminal and juvenile justice. To this end, the Board currently operates with six (6) subcommittees: National Institute of Justice (NIJ); Bureau of Justice Statistics (BJS); Office of Juvenile Justice and Delinquency Prevention (OJJDP); Bureau of Justice Assistance (BJA); Quality and Protection of Science; and Evidence Translation/ Integration.

DATES: Nominations will be accepted through August 29, 2014.

FOR FURTHER INFORMATION CONTACT:

Phelan Wyrick, Designated Federal Officer (DFO), Office of the Assistant Attorney General, Office of Justice Programs, 810 7th Street Northwest, Washington, DC 20531; Phone: (202) 353–9254 [Note: this is not a toll-free number]; Email: phelan.wyrick@usdoj.gov.

SUPPLEMENTARY INFORMATION: To make a nomination, please contact Mr. Wyrick (see above for addresses and phone numbers). Nominations should include the name, title, affiliation, and contact information for the nominee. Resumes, statements of interest, and other relevant supporting information are welcome. Self-nominations are welcome.

The Board typically meets twice a year to brief the OJP Assistant Attorney General and the Board members on the progress of the subcommittees, discuss any recommendations they may have for consideration by the full SAB, and brief the Board on various OJP-related projects and activities. All meetings of the Board take place in Washington, DC. The Board is a federal advisory committee covered under the Federal Advisory Committee Act, and as such, meetings of the Board are open to the public. Members of the Board include scientists and practitioners with strong backgrounds of applying science in the fields of criminal justice, juvenile justice, or crime victim services. Current